跳至主要内容
临床试验/ISRCTN85216856
ISRCTN85216856进行中(未招募)2 期

Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration: IMPACT

niversidad Tecnológica Equinoccial0 个研究点目标入组 200 人开始时间: 2020年5月11日最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged =18 years
  • 2. Clinical, molecular (using IgM/IgG or RT-PCR), or lung imaging diagnosis of COVID-19
  • 3. Deterioration of previously normal lung function defined as SaO2 of <90% in 0.5 FiO2, and/or a higher requirement of O2 than in the previous 24h
  • 4. A score of 5 to 7 on the early warning scale for COVID-19 patients or a SOFA score between 2 and 10
  • 5. Informed consent provided by patients or their representatives

排除标准

  • 1. Diagnosis and/or treatment for cancer
  • 2. HIV infection
  • 3. Currently receiving immunosuppressants for a condition other than SARS-CoV2 infection
  • 4. Superimposed systemic infections
  • 5. Liver or kidney failure
  • 6. COPD, previous pulmonary fibrosis, and/or restrictive lung disease
  • 7. Have received previous transfusions

研究者

发起方
niversidad Tecnológica Equinoccial

相似试验